Related Experiment Video
Updated: Jan 4, 2026
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Pediatric asthma: Principles and treatment
Insights
Pediatric asthma often begins before age three, with symptoms like wheezing and cough triggered by infections or environmental factors. Early diagnosis and consistent treatment, including inhaled corticosteroids, are key to managing childhood asthma effectively.
Area of Science:
- Pediatric Pulmonology
- Allergy and Immunology
- Pediatric Asthma Management
Background:
- Asthma commonly manifests in children under three years old, often presenting as recurrent wheezing and cough.
- Symptoms are frequently triggered by viral upper respiratory infections (URIs), physical activity, or environmental changes.
- Children with asthma may experience prolonged recovery from respiratory symptoms following viral infections.
Purpose of the Study:
- To outline the diagnostic indicators and therapeutic strategies for pediatric asthma.
- To emphasize the importance of trigger avoidance and consistent controller therapy.
- To discuss current treatment guidelines and advanced therapeutic options for persistent asthma.
Main Methods:
- Clinical history review focusing on triggers (URI, exercise, weather) and symptom patterns.
- Assessment of symptom frequency and nocturnal awakenings to classify asthma persistence.
- Evaluation of response to bronchodilator therapy and adherence to controller medications.
- Consideration of skin-prick testing for allergen identification.
- Review of treatment guidelines, including inhaled corticosteroids (ICS) and montelukast.
- Discussion of advanced therapies like long-acting beta-2 adrenergic agonists (in combination with ICS) and biologic agents for severe cases.
Main Results:
- Recurrent wheezing/cough, prolonged recovery post-URI, and exercise-induced symptoms suggest pediatric asthma.
- Persistent asthma (symptoms >2 days/week or 2 nights/month) warrants daily controller therapy, with ICS as the preferred choice.
- Montelukast offers an oral alternative for children aged 12 months and older.
- Biologic therapies are available for severe or difficult-to-control asthma phenotypes.
Conclusions:
- Effective pediatric asthma management involves identifying triggers, consistent controller therapy, and adherence to guidelines.
- Inhaled corticosteroids are the cornerstone of daily controller therapy for persistent asthma in children.
- Individualized treatment plans, including newer biologic agents, are crucial for managing diverse asthma phenotypes.
Abstract:
Approximately one-half of children with asthma present with symptoms before 3 years of age. The typical history describes recurrent episodes of wheezing and/or cough triggered by a viral upper respiratory infection (URI), activity, or changes in weather. When symptoms occur after a viral URI, children with asthma often take longer than the usual week to fully recover from their respiratory symptoms. Wheezing and coughing during exercise or during laughing or crying, and episodes triggered in the absence of infection suggest asthma. A trial of bronchodilator medication should show symptomatic improvement. The goal of asthma therapy is to keep children "symptom free" by preventing chronic symptoms, maintaining lung function, and allowing for normal daily activities. Avoidance of triggers identified by a history, such as second-hand cigarette smoke exposure, and allergens identified by skin-prick testing can significantly reduce symptoms. According to the 2007 National Asthma Education and Prevention Program (NAEPP) report, if impairment symptoms are present for >2 days/week or 2 nights/month, then the disease process is characterized as persistent, and, in all age groups, inhaled corticosteroids (ICS) are recommended as the preferred daily controller therapy. Montelukast is approved for children ages ≥ 12 months and is often used for its ease of daily oral dosing. Long-acting beta-2 adrenergic agonists should only be used in combination with an ICS. For more-severe or difficult-to-control phenotypes, biologic therapy has been developed, which targets the type of inflammation present.
Related Concept Videos
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:29Asthma-I: Introduction
01:30Asthma-IV: Nursing Management
First, in...
01:26Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...